bluuebunny/crossref_metadata_2025 huggingface dataset:
Sl Table 1-6 from Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Authors: Li Qiao , Guan Xiuwen , Chen Shanshan , Yi Zongbi , Lan Bo , Xing Puyuan , Fan Ying , Wang Jiayu , Luo Yang , Yuan Peng , Cai Ruigang , Zhang Pin , Li Qing , Zhong Dafang , Zhang Yifan , Zou Jianjun , Zhu Xiaoyu , Ma Fei , Xu Binghe
Published: April 2023

Sl Table 1. Management of diarrhea during pyrotinib plus capecitabine treatment Sl Table 2. Occurrence and recovery of treatment-related diarrhea in different Pyrotinib dose cohorts Sl Table 3. Occurrence and management of treatment-related Grade 3 or higher diarrhea in different Pyrotinib dose cohorts Sl Table 4. The incidence of Grade 1 to 5 diarrheal events in different Pyrotinib dose cohorts Sl Table 5. The incidence of Grade 1 to 5 treatment-related adverse events of diarrhea, palmar-plantar erythrodysesthesia syndrome (PPE), oral ulceration and rash. Sl Table 6. The best overall response rate and clinical benefit rate of patients in different pyrotinib dose cohorts according to different prior trastuzumab exposure.
Supplementary Table S2 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Table S2. Smartpool siRNAs used to confirm compound identity.
Supplementary Table S1 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Table S1. Complete list of compounds screened.
Supplementary Figure 2 from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Authors: Flaifel Abdallah , Xie Wanling , Braun David A. , Ficial Miriam , Bakouny Ziad , Nassar Amin H. , Jennings Rebecca B. , Escudier Bernard , George Daniel J. , Motzer Robert J. , Morris Michael J. , Powles Thomas , Wang Evelyn , Huang Ying , Freeman Gordon J. , Choueiri Toni K. , Signoretti Sabina
Published: April 2023

Figure S2 shows IHC image analysis workflow
Tables S1, S2, S3, S4, S5. Figures S1, S2. from Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Authors: Xu Wenxin , Puligandla Maneka , Manola Judith , Bullock Andrea J. , Tamasauskas Daniel , McDermott David F. , Atkins Michael B. , Haas Naomi B. , Flaherty Keith , Uzzo Robert G. , Dutcher Janice P. , DiPaola Robert S. , Bhatt Rupal S.
Published: April 2023

Supplemental Table 1: Catalog numbers for MSD assays Supplemental Figure 1: Hazard ratio for CXCL10 and DFS by treatment arm Supplemental Figure 2: Assessment of log-linearity for relationship between IP-10 and recurrence risk Supplemental Table 2: Median changes in cytokines at weeks 4 and 6 Supplemental Table 3: Relationship between on-treatment cytokine levels and DFS Supplemental Table 4: Subset analysis for cytokine changes among patients who did not recur Supplemental Table 5: Evaluation for interaction effects between treatment arm and the association between baseline CXCL10 and DFS
Supplementary Tables S1 and S2 from Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
Authors: Labadie Brian W. , Bao Riyue , Luke Jason J.
Published: April 2023

Supplementary Tables S1 and S2
Table S1 from Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
Authors: Bernemann Christof , Humberg Verena , Thielen Barbara , Steinestel Julie , Chen Xin , Duensing Stefan , Schrader Andres J. , Boegemann Martin
Published: April 2023

Primer sequences
Supplementary Table 1 from Bioactivation of Napabucasin Triggers Reactive Oxygen Species–Mediated Cancer Cell Death
Authors: Froeling Fieke E.M. , Swamynathan Manojit Mosur , Deschênes Astrid , Chio Iok In Christine , Brosnan Erin , Yao Melissa A. , Alagesan Priya , Lucito Matthew , Li Juying , Chang An-Yun , Trotman Lloyd C. , Belleau Pascal , Park Youngkyu , Rogoff Harry A. , Watson James D. , Tuveson David A.
Published: April 2023

Table listing the differentially expressed genes between napabucasin treated cells compared to DMSO as vehicle control
Supplementary Table S2 from Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Authors: Sharifi Zeinab , Abdulkarim Bassam , Meehan Brian , Rak Janusz , Daniel Paul , Schmitt Julie , Lauzon Nidia , Eppert Kolja , Duncan Heather M. , Petrecca Kevin , Guiot Marie-Christine , Jean-Claude Bertrand , Sabri Siham
Published: April 2023

Table S2 summarizes IC50s of TMZ, gefitinib or ZR2002 for various GSCs.
Supplementary Figure S4 from Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Authors: Sharifi Zeinab , Abdulkarim Bassam , Meehan Brian , Rak Janusz , Daniel Paul , Schmitt Julie , Lauzon Nidia , Eppert Kolja , Duncan Heather M. , Petrecca Kevin , Guiot Marie-Christine , Jean-Claude Bertrand , Sabri Siham
Published: April 2023

Figure S4 shows body weights assessment for mice with orthotopic U87/EGFRvIII (A) or TMZ-resistant GSC (1123IC7R) tumors (B) treated with vehicle control or ZR2002 using alternate (A) or continuous treatment (B).
Supplementary Data from Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma
Authors: Qin Yi , Wu Chung W. , Taylor William R. , Sawas Tarek , Burger Kelli N. , Mahoney Douglas W. , Sun Zhifu , Yab Tracy C. , Lidgard Graham P. , Allawi Hatim T. , Buttar Navtej S. , Smyrk Thomas C. , Iyer Prasad G. , Katzka David A. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Figure 2. Box plots of methylated DNA marker levels in various types of cancers were made from publically available hybridization array data from The Cancer Genome Atlas.
Supplementary Figure S3 from Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Authors: Sharifi Zeinab , Abdulkarim Bassam , Meehan Brian , Rak Janusz , Daniel Paul , Schmitt Julie , Lauzon Nidia , Eppert Kolja , Duncan Heather M. , Petrecca Kevin , Guiot Marie-Christine , Jean-Claude Bertrand , Sabri Siham
Published: April 2023

Figure S3 shows ZR2002 alternate (schedule#1) or continuous (schedule#2) treatment protocol (A) and monitoring mice body weights for alternate (B) or continuous (C) treatment.
Supplementary Figure 7 from Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide
Authors: Sharifi Zeinab , Abdulkarim Bassam , Meehan Brian , Rak Janusz , Daniel Paul , Schmitt Julie , Lauzon Nidia , Eppert Kolja , Duncan Heather M. , Petrecca Kevin , Guiot Marie-Christine , Jean-Claude Bertrand , Sabri Siham
Published: April 2023

Figure S7 provides evidence for the presence and co-localization of ZR2002 with its dealkylated metabolite ZR01, a potent EGFR inhibitor using MALDI IMS in brain tumor tissue.
Supplementary Tables from Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma
Authors: Dieters-Castator Dylan Z. , Rambau Peter F. , Kelemen Linda E. , Siegers Gabrielle M. , Lajoie Gilles A. , Postovit Lynne-Marie , Köbel Martin
Published: April 2023

Patient characteristics, instrument settings, protein identifications, staining information, and pathway analysis.
Figure S8 from The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Authors: Heisey Daniel A.R. , Lochmann Timothy L. , Floros Konstantinos V. , Coon Colin M. , Powell Krista M. , Jacob Sheeba , Calbert Marissa L. , Ghotra Maninderjit S. , Stein Giovanna T. , Maves Yuki Kato , Smith Steven C. , Benes Cyril H. , Leverson Joel D. , Souers Andrew J. , Boikos Sosipatros A. , Faber Anthony C.
Published: April 2023

DNA damage is increased with the combination of olaparib and navitoclax
Figure S4 from The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Authors: Heisey Daniel A.R. , Lochmann Timothy L. , Floros Konstantinos V. , Coon Colin M. , Powell Krista M. , Jacob Sheeba , Calbert Marissa L. , Ghotra Maninderjit S. , Stein Giovanna T. , Maves Yuki Kato , Smith Steven C. , Benes Cyril H. , Leverson Joel D. , Souers Andrew J. , Boikos Sosipatros A. , Faber Anthony C.
Published: April 2023

A chemotherapy naive and chemotherapy resistant cell line pair respond differently to chemotherapeutics
Figures S1-12 from Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
Authors: Jonsson Philip , Lin Andrew L. , Young Robert J. , DiStefano Natalie M. , Hyman David M. , Li Bob T. , Berger Michael F. , Zehir Ahmet , Ladanyi Marc , Solit David B. , Arnold Angela G. , Stadler Zsofia K. , Mandelker Diana , Goldberg Michael E. , Chmielecki Juliann , Pourmaleki Maryam , Ogilvie Shahiba Q. , Chavan Shweta S. , McKeown Andrew T. , Manne Malbora , Hyde Allison , Beal Kathryn , Yang T. Jonathan , Nolan Craig P. , Pentsova Elena , Omuro Antonio , Gavrilovic Igor T. , Kaley Thomas J. , Diamond Eli L. , Stone Jacqueline B. , Grommes Christian , Boire Adrienne , Daras Mariza , Piotrowski Anna F. , Miller Alexandra M. , Gutin Philip H. , Chan Timothy A. , Tabar Viviane S. , Brennan Cameron W. , Rosenblum Marc , DeAngelis Lisa M. , Mellinghoff Ingo K. , Taylor Barry S.
Published: April 2023

Figure S1: Distribution of systemic therapies received. Figure S2: Number of sequenced samples per patient. Figure S3: Subgroup-defining genomic lesions in IDH-wildtype and -mutant gliomas. Figure S4: Frequency of mutations in primary tumors. Figure S5: Frequency of glioma type-defining genes. Figure S6: Outcome by enhancement and cell-cycle alteration status. Figure S7: Alteration of key functional groups in IDH-WT astrocytic tumors. Figure S8: Cell-cycle alterations and outcome in 1p19q-intact IDH WT tumors. Figure S9: Rate of alkylating therapy-induced hypermutation by WHO class. Figure S10: Frequency of actionable alterations. Figure S11: BRAF hotspot mutations in glioma. Figure S12: MR brain images for three patients receiving MAPK-directed therapy.
Table S1 from Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction
Authors: Carbajosa Sofía , Pansa María Florencia , Paviolo Natalia S. , Castellaro Andrés M. , Andino Diego L. , Nigra Ayelén D. , García Iris Alejandra , Racca Ana C. , Rodriguez-Berdini Lucía , Angiolini Virginia , Guantay Laura , Villafañez Florencia , Federico María Belén , Rodríguez-Baili María Celeste , Caputto Beatriz L. , Drewes Gerard , Madauss Kevin P. , Gloger Israel , Fernandez Elmer , Gil Germán A. , Bocco José Luis , Gottifredi Vanesa , Soria Gastón
Published: April 2023

Full list of hits of the BRCA1-deficient population in the screening performed with the PKIS2 library
Figure S5 from Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction
Authors: Carbajosa Sofía , Pansa María Florencia , Paviolo Natalia S. , Castellaro Andrés M. , Andino Diego L. , Nigra Ayelén D. , García Iris Alejandra , Racca Ana C. , Rodriguez-Berdini Lucía , Angiolini Virginia , Guantay Laura , Villafañez Florencia , Federico María Belén , Rodríguez-Baili María Celeste , Caputto Beatriz L. , Drewes Gerard , Madauss Kevin P. , Gloger Israel , Fernandez Elmer , Gil Germán A. , Bocco José Luis , Gottifredi Vanesa , Soria Gastón
Published: April 2023

Legends included in the figure file
Supplementary tables from Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Authors: Spratt Daniel E. , Alshalalfa Mohammed , Fishbane Nick , Weiner Adam B. , Mehra Rohit , Mahal Brandon A. , Lehrer Jonathan , Liu Yang , Zhao Shuang G. , Speers Corey , Morgan Todd M. , Dicker Adam P. , Freedland Stephen J. , Karnes R. Jeffery , Weinmann Sheila , Davicioni Elai , Ross Ashley E. , Den Robert B. , Nguyen Paul L. , Feng Felix Y. , Lotan Tamara L. , Chinnaiyan Arul M. , Schaeffer Edward M.
Published: April 2023

Table S1-3
Supplementary Table S3 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy
Authors: Klanova Magdalena , Oestergaard Mikkel Z. , Trněný Marek , Hiddemann Wolfgang , Marcus Robert , Sehn Laurie H. , Vitolo Umberto , Bazeos Alexandra , Goede Valentin , Zeuner Harald , Knapp Andrea , Sahin Deniz , Spielewoy Nathalie , Bolen Christopher R. , Cardona Andres , Klein Christian , Venstrom Jeffrey M. , Nielsen Tina , Fingerle-Rowson Günter
Published: April 2023

Risk or severity of infections by NKCC (A) and by NKCC and treatment arm (B) in FL and DLBCL.
Supplementary Figure 6 from Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Authors: Guillén Díaz-Maroto Natalia , Sanz-Pamplona Rebeca , Berdiel-Acer Mireia , Cimas Francisco J. , García Elena , Gonçalves-Ribeiro Samuel , Albert Nerea , Garcia-Vicién Gemma , Capella Gabriel , Moreno Victor , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

Supplementary Figure 6 A and B
Supplementary Figure 2 from Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Authors: Guillén Díaz-Maroto Natalia , Sanz-Pamplona Rebeca , Berdiel-Acer Mireia , Cimas Francisco J. , García Elena , Gonçalves-Ribeiro Samuel , Albert Nerea , Garcia-Vicién Gemma , Capella Gabriel , Moreno Victor , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

Supplementary Figure 2
Supplementary Table S8 from Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling
Authors: Ji Jianxiong , Xu Ran , Ding Kaikai , Bao Guoqing , Zhang Xin , Huang Bin , Wang Xinyu , Martinez Aurora , Wang Xiuying , Li Gang , Miletic Hrvoje , Thorsen Frits , Bjerkvig Rolf , Xiang Lei , Han Bo , Chen Anjing , Li Xingang , Wang Jian
Published: April 2023

Association between ACTN4 expression and clinicopathological factors in glioma
Supplementary Table S2-S4 from Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling
Authors: Ji Jianxiong , Xu Ran , Ding Kaikai , Bao Guoqing , Zhang Xin , Huang Bin , Wang Xinyu , Martinez Aurora , Wang Xiuying , Li Gang , Miletic Hrvoje , Thorsen Frits , Bjerkvig Rolf , Xiang Lei , Han Bo , Chen Anjing , Li Xingang , Wang Jian
Published: April 2023

Oligonucleotide sets used, Plasmids used and Primer sets used in this study
Supplementary Materials and Methods from Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling
Authors: Ji Jianxiong , Xu Ran , Ding Kaikai , Bao Guoqing , Zhang Xin , Huang Bin , Wang Xinyu , Martinez Aurora , Wang Xiuying , Li Gang , Miletic Hrvoje , Thorsen Frits , Bjerkvig Rolf , Xiang Lei , Han Bo , Chen Anjing , Li Xingang , Wang Jian
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure 2 from Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer
Authors: Montanuy Helena , Martínez-Barriocanal Águeda , Antonio Casado José , Rovirosa Llorenç , Ramírez Maria José , Nieto Rocío , Carrascoso-Rubio Carlos , Riera Pau , González Alan , Lerma Enrique , Lasa Adriana , Carreras-Puigvert Jordi , Helleday Thomas , Bueren Juan A. , Arango Diego , Minguillón Jordi , Surrallés Jordi
Published: April 2023

Figure S2. Additional data on gefitinib and afatinib in vivo mouse xenograft experiments. Weight control.
Figure S1 from Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study
Authors: Qiao Guoliang , Wang Xiaoli , Zhou Lei , Zhou Xinna , Song Yuguang , Wang Shuo , Zhao Lei , Morse Michael A. , Hobeika Amy , Song Jin , Yi Xin , Xia Xuefeng , Ren Jun , Lyerly Herbert Kim
Published: April 2023

A. Tumor burden decreased significantly after treatment with DC-CIK infusions in four patients respectively; B. Mutation profiles of 30 patients in the groups of DC-CIK combined with S-1(DS) and DC-CIK combined with S-1 plus cisplatin (DSC); C. Comparison of number of gene mutations in all 30 patients pre-DC-CIK with post-DC-CIK; D. comparison of frequency of ctDNA mutations in all 30 patients pre-DC-CIK with post- DC-CIK. E: Statistical analysis of comparison of number of gene mutations in all 30 patients pre-DC-CIK with post-DC-CIK (p<0.05); F: Statistical analysis of comparison of frequency of ctDNA mutations in all 30 patients pre-DC-CIK with post- DC-CIK(p<0.05).
Table S2 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Authors: Yan Zi-Xun , Li Li , Wang Wen , OuYang Bin-Shen , Cheng Shu , Wang Li , Wu Wen , Xu Peng-Peng , Muftuoglu Muharrem , Hao Ming , Yang Su , Zhang Mu-Chen , Zheng Zhong , Li James , Zhao Wei-Li
Published: April 2023

Supplementary Table S2: Amount and potency of CAR T cells
Supplementary Figures from Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer
Authors: Lee Jong Bok , Kang Hyeonjeong , Fang Linan , D'Souza Cheryl , Adeyi Oyedele , Zhang Li
Published: April 2023

Supplementary Figures
Table S1 from Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Katagi Hiroaki , Louis Nundia , Unruh Dusten , Sasaki Takahiro , He Xingyao , Zhang Ali , Ma Quanhong , Piunti Andrea , Shimazu Yosuke , Lamano Jonathan B. , Carcaboso Angel M. , Tian Xiao , Seluanov Andrei , Gorbunova Vera , Laurie Kathryn L. , Kondo Akihide , Wadhwani Nitin R. , Lulla Rishi , Goldman Stewart , Venneti Sriram , Becher Oren J. , Zou Lihua , Shilatifard Ali , Hashizume Rintaro
Published: April 2023

Supplementary Table S1
Table S2 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors
Authors: Kieran Mark W. , Geoerger Birgit , Dunkel Ira J. , Broniscer Alberto , Hargrave Darren , Hingorani Pooja , Aerts Isabelle , Bertozzi Anne-Isabelle , Cohen Kenneth J. , Hummel Trent R. , Shen Violet , Bouffet Eric , Pratilas Christine A. , Pearson Andrew D.J. , Tseng Lillian , Nebot Noelia , Green Steven , Russo Mark W. , Whitlock James A.
Published: April 2023

Dabrafenib dosing
Table S1 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors
Authors: Kieran Mark W. , Geoerger Birgit , Dunkel Ira J. , Broniscer Alberto , Hargrave Darren , Hingorani Pooja , Aerts Isabelle , Bertozzi Anne-Isabelle , Cohen Kenneth J. , Hummel Trent R. , Shen Violet , Bouffet Eric , Pratilas Christine A. , Pearson Andrew D.J. , Tseng Lillian , Nebot Noelia , Green Steven , Russo Mark W. , Whitlock James A.
Published: April 2023

Global study locations for the phase 1 part of the study
Figure S6 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Authors: Zhang Jiu-Yang , Zhang Pei-Pei , Zhou Wen-Ping , Yu Jia-Yu , Yao Zhi-Hua , Chu Jun-Feng , Yao Shu-Na , Wang Cheng , Lone Waseem , Xia Qing-Xin , Ma Jie , Yang Shu-Jun , Liu Kang-Dong , Dong Zi-Gang , Guo Yong-Jun , Smith Lynette M. , McKeithan Timothy W. , Chan Wing C. , Iqbal Javeed , Liu Yan-Yan
Published: April 2023

Figure S6 shows the knockout of CACNA1C using CRISPR/Cas9 system.The expression of CACNA1C was knockout using its sgRNA1 and 5 CRISPR/Cas9 system, which resulted in the obvious apoptosis of these edited cells.
Figure S4 from Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Authors: Du Fang , Yuelling Larra , Lee Eric H. , Wang Yuan , Liao Shengyou , Cheng Yan , Zhang Li , Zheng Chaonan , Peri Suraj , Cai Kathy Q. , Ng Jessica M.Y. , Curran Tom , Li Peng , Yang Zeng-jie
Published: April 2023

Figure S4
Supplementary Methods from Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study
Authors: Kang Shin-Ae , Guan Jye Swei , Tan Hock Jin , Chu Tinghine , Thike Aye Aye , Bernadó Cristina , Arribas Joaquín , Wong Chow Yin , Tan Puay Hoon , Gudi Mihir , Putti Thomas Choudary , Sohn Joohyuk , Lim Swee Ho , Lee Soo Chin , Lim Yoon Pin
Published: April 2023

Supplementary Methods
Supplementary Figure from Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study
Authors: Kang Shin-Ae , Guan Jye Swei , Tan Hock Jin , Chu Tinghine , Thike Aye Aye , Bernadó Cristina , Arribas Joaquín , Wong Chow Yin , Tan Puay Hoon , Gudi Mihir , Putti Thomas Choudary , Sohn Joohyuk , Lim Swee Ho , Lee Soo Chin , Lim Yoon Pin
Published: April 2023

Supplementary Figure 1 and 2
Supplemental Information from Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation
Authors: Yun Eun-Jin , Lin Chun-Jung , Dang Andrew , Hernandez Elizabeth , Guo Jiaming , Chen Wei-Min , Allison Joyce , Kim Nathan , Kapur Payal , Brugarolas James , Wu Kaijie , He Dalin , Lai Chih-Ho , Lin Ho , Saha Debabrata , Baek Seung Tae , Chen Benjamin P.C. , Hsieh Jer-Tsong
Published: April 2023

Figure S1. DAB2IP expression does not affect key repair factors in NHEJ (Ku70, Ku80) and HR (RAD51, BRCA1) and PARP-1 mRNA expression. Figure S2. RANBP2, TRIP12, and RNF40 interact with both DAB2IP and PARP-1. Figure S3. Radiotherapy of RCC xenograft models.
Supplementary Data from The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Authors: Truini Anna , Starrett Jacqueline H. , Stewart Tyler , Ashtekar Kumar , Walther Zenta , Wurtz Anna , Lu David , Park Jin H. , DeVeaux Michelle , Song Xiaoling , Gettinger Scott , Zelterman Daniel , Lemmon Mark A. , Goldberg Sarah B. , Politi Katerina
Published: April 2023

Table S1 and Table S2
Supplementary Table S1: Preferred Terms included in Grouped Terms from FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia
Authors: Norsworthy Kelly J. , By Kunthel , Subramaniam Sriram , Zhuang Luning , Del Valle Pedro L. , Przepiorka Donna , Shen Yuan-Li , Sheth Christopher M. , Liu Chao , Leong Ruby , Goldberg Kirsten B. , Farrell Ann T. , Pazdur Richard
Published: April 2023

Supplementary Table S1
Online Figure 2 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm
Authors: van der Voort Sebastian R. , Incekara Fatih , Wijnenga Maarten M.J. , Kapas Georgios , Gardeniers Mayke , Schouten Joost W. , Starmans Martijn P.A. , Nandoe Tewarie Rishie , Lycklama Geert J. , French Pim J. , Dubbink Hendrikus J. , van den Bent Martin J. , Vincent Arnaud J.P.E. , Niessen Wiro J. , Klein Stefan , Smits Marion
Published: April 2023

Overview of importance of imaging and demographic features
Table S7 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Table S7 shows the cytokine profiles of neutrophils and TINs.
Figure S2 from Tumor-Contacted Neutrophils Promote Metastasis by a CD90-TIMP-1 Juxtacrine–Paracrine Loop
Authors: Wang Ying , Chen Jianing , Yang Linbin , Li Jiaqian , Wu Wei , Huang Min , Lin Ling , Su Shicheng
Published: April 2023

Figure S2 shows the CD66 expression and apoptosis of neutrophils cultured ex vivo for 48 hours.
Suppl Figure 1 from AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival
Authors: Cosimo Emilio , Tarafdar Anuradha , Moles Michael W. , Holroyd Ailsa K. , Malik Natasha , Catherwood Mark A. , Hay Jodie , Dunn Karen M. , Macdonald Alan M. , Guichard Sylvie M. , O'Rourke Declan , Leach Michael T. , Sansom Owen J. , Cosulich Sabina C. , McCaig Alison M. , Michie Alison M.
Published: April 2023

Suppl Figure 1
Table S6 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
Authors: Fang Wenfeng , Ma Yuxiang , Yin Jiani C. , Hong Shaodong , Zhou Huaqiang , Wang Ao , Wang Fufeng , Bao Hua , Wu Xue , Yang Yunpeng , Huang Yan , Zhao Hongyun , Shao Yang W. , Zhang Li
Published: April 2023

Impact of copy number loss in genes in immune-related pathways on immunotherapy response in Miao et al and our data
Supplementary Figure 1 from Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Authors: Chen Robert , Herrera Alex F. , Hou Jessie , Chen Lu , Wu Jun , Guo Yuming , Synold Timothy W. , Ngo Vu N. , Puverel Sandrine , Mei Matthew , Popplewell Leslie , Yi Shuhua , Song Joo Y. , Tao Shu , Wu Xiwei , Chan Wing C. , Forman Stephen J. , Kwak Larry W. , Rosen Steven T. , Newman Edward M.
Published: April 2023

Supplementary Figure 1
Supplementary Figure description from Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases
Authors: Kawaguchi Yoshikuni , Kopetz Scott , Newhook Timothy E. , De Bellis Mario , Chun Yun Shin , Tzeng Ching-Wei D. , Aloia Thomas A. , Vauthey Jean-Nicolas
Published: April 2023

Supplementary Figure description
Supplementary Figure 2 from Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases
Authors: Kawaguchi Yoshikuni , Kopetz Scott , Newhook Timothy E. , De Bellis Mario , Chun Yun Shin , Tzeng Ching-Wei D. , Aloia Thomas A. , Vauthey Jean-Nicolas
Published: April 2023

Supplementary Figure 2. Prevalence of somatic gene mutations among 507 patients undergoing resection of colorectal liver metastases.
Supplementary Table 1 from TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Authors: Rimawi Mothaffar F. , Niravath Polly , Wang Tao , Rexer Brent N. , Forero Andres , Wolff Antonio C. , Nanda Rita , Storniolo Anna M. , Krop Ian , Goetz Matthew P. , Nangia Julie R. , Jiralerspong Sao , Pavlick Anne , Veeraraghavan Jamunarani , De Angelis Carmine , Gutierrez Carolina , Schiff Rachel , Hilsenbeck Susan G. , Osborne C. Kent
Published: April 2023

Treatment discontinuation in TBCRC023 Patients
Figure S1, Figure S2, Figure S3; source file format .docx from Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers
Authors: Guindalini Rodrigo Santa Cruz , Zheng Yonglan , Abe Hiroyuki , Whitaker Kristen , Yoshimatsu Toshio F. , Walsh Tom , Schacht David , Kulkarni Kirti , Sheth Deepa , Verp Marion S. , Bradbury Angela R. , Churpek Jane , Obeid Elias , Mueller Jeffrey , Khramtsova Galina , Liu Fang , Raoul Akila , Cao Hongyuan , Romero Iris L. , Hong Susan , Livingston Robert , Jaskowiak Nora , Wang Xiaoming , Debiasi Marcio , Pritchard Colin C. , King Mary-Claire , Karczmar Gregory , Newstead Gillian M. , Huo Dezheng , Olopade Olufunmilayo I.
Published: April 2023

Figure S1. Study protocol design; Figure S2. MRI compliance during the first 5 years of study; Figure S3. Recall and biopsy rates by imaging modality
Table S1 from Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy
Authors: Xie Feng , Zhang Jianjun , Wang Jiayin , Reuben Alexandre , Xu Wei , Yi Xin , Varn Frederick S. , Ye Yongsheng , Cheng Junwen , Yu Miao , Wang Yue , Liu Yufeng , Xie Mingchao , Du Peng , Ma Ke , Ma Xin , Zhou Penghui , Yang Shengli , Chen Yaobing , Wang Guoping , Xia Xuefeng , Liao Zhongxing , Heymach John V. , Wistuba Ignacio I. , Futreal P. Andrew , Ye Kai , Cheng Chao , Xia Tian
Published: April 2023

Table S1 describes the Cancer Genome Atlas (TCGA) samples across 29 tumor types.
Table S1, Table S2 from E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
Authors: Tarhini Ahmad A. , Lee Sandra J. , Li Xiaoxue , Rao Uma N.M. , Nagarajan Arun , Albertini Mark R. , Mitchell Jerry W. , Wong Stuart J. , Taylor Mark A. , Laudi Noel , Truong Phu V. , Conry Robert M. , Kirkwood John M.
Published: April 2023

Table S1- Tumor response by RECIST criteria. Table S2- Treatment details and reasons for discontinuation.
Supplementary Data from Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo
Authors: Woods Brittany , Chen Wei , Chiu Sophia , Marinaccio Christian , Fu Chunling , Gu Lilly , Bulic Marinka , Yang Qiong , Zouak Anouar , Jia Shengxian , Suraneni Praveen Kumar , Xu Kailin , Levine Ross L. , Crispino John D. , Wen Qiang Jeremy
Published: April 2023

Supplementary figures and figure legends
Supplementary Figures S1-S6 from Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma
Authors: Dong Lei , You Shuo , Zhang Qing , Osuka Satoru , Devi Narra S. , Kaluz Stefan , Ferguson Jalisa H. , Yang Hua , Chen Guoliang , Wang Binghe , Grossniklaus Hans E. , Van Meir Erwin G.
Published: April 2023

Suppl. Figs. S1-S6
Figure S3 from Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Authors: Crosby Erika J. , Gwin William , Blackwell Kimberly , Marcom Paul K. , Chang Serena , Maecker Holden T. , Broadwater Gloria , Hyslop Terry , Kim Sungjin , Rogatko Andre , Lubkov Veronica , Snyder Joshua C. , Osada Takuya , Hobeika Amy C. , Morse Michael A. , Lyerly H. Kim , Hartman Zachary C.
Published: April 2023

SPADE tree generated by CYTOF analysis
Figure S1 from Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Authors: Crosby Erika J. , Gwin William , Blackwell Kimberly , Marcom Paul K. , Chang Serena , Maecker Holden T. , Broadwater Gloria , Hyslop Terry , Kim Sungjin , Rogatko Andre , Lubkov Veronica , Snyder Joshua C. , Osada Takuya , Hobeika Amy C. , Morse Michael A. , Lyerly H. Kim , Hartman Zachary C.
Published: April 2023

Patient cohort schematic
Table S2 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Authors: Gartrell Robyn D. , Marks Douglas K. , Rizk Emanuelle M. , Bogardus Margaret , Gérard Camille L. , Barker Luke W. , Fu Yichun , Esancy Camden L. , Li Gen , Ji Jiayi , Rui Shumin , Ernstoff Marc S. , Taback Bret , Pabla Sarabjot , Chang Rui , Lee Sandra J. , Krolewski John J. , Morrison Carl , Horst Basil A. , Saenger Yvonne M.
Published: April 2023

Patient characteristics in metastasis cohort.
Figure S03 from Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Authors: Hutchinson Katherine E. , Yost Susan E. , Chang Ching-Wei , Johnson Radia Marie , Carr Adrian R. , McAdam Paul R. , Halligan Daniel L. , Chang Chun-Chieh , Schmolze Daniel , Liang Jackson , Yuan Yuan
Published: April 2023

PAM50 subtype analysis, TILs by breast cancer subtypes
Figure S02 from Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Authors: Hutchinson Katherine E. , Yost Susan E. , Chang Ching-Wei , Johnson Radia Marie , Carr Adrian R. , McAdam Paul R. , Halligan Daniel L. , Chang Chun-Chieh , Schmolze Daniel , Liang Jackson , Yuan Yuan
Published: April 2023

Supplementary genomics tileplot.
Figure S3 from Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
Authors: Gartrell Robyn D. , Marks Douglas K. , Rizk Emanuelle M. , Bogardus Margaret , Gérard Camille L. , Barker Luke W. , Fu Yichun , Esancy Camden L. , Li Gen , Ji Jiayi , Rui Shumin , Ernstoff Marc S. , Taback Bret , Pabla Sarabjot , Chang Rui , Lee Sandra J. , Krolewski John J. , Morrison Carl , Horst Basil A. , Saenger Yvonne M.
Published: April 2023

MIP correlates with OS.
Supplementary Data from Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial
Authors: Bernard-Tessier Alice , Jeannot Emmanuelle , Guenat David , Debernardi Alice , Michel Marc , Proudhon Charlotte , Vincent-Salomon Anne , Bièche Ivan , Pierga Jean-Yves , Buecher Bruno , Meurisse Aurélia , François Éric , Cohen Romain , Jary Marine , Vendrely Véronique , Samalin Emmanuelle , El Hajbi Farid , Baba-Hamed Nabil , Borg Christophe , Bidard François-Clément , Kim Stefano
Published: April 2023

Supplementary materials and figures
Figure S1 from Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial
Authors: Bernard-Tessier Alice , Jeannot Emmanuelle , Guenat David , Debernardi Alice , Michel Marc , Proudhon Charlotte , Vincent-Salomon Anne , Bièche Ivan , Pierga Jean-Yves , Buecher Bruno , Meurisse Aurélia , François Éric , Cohen Romain , Jary Marine , Vendrely Véronique , Samalin Emmanuelle , El Hajbi Farid , Baba-Hamed Nabil , Borg Christophe , Bidard François-Clément , Kim Stefano
Published: April 2023

Figure S1 shows a comparison of quantitative HPV ctDNA at baseline with ddPCR assay and QPCR assay (Spearman r=0.803, 95% CI 0.672 to 0.885, P<0.001).
Supplementary table legend from Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases
Authors: Bergen Elisabeth S. , Berghoff Anna S. , Medjedovic Mela , Rudas Margaretha , Fitzal Florian , Bago-Horvath Zsuzsanna , Dieckmann Karin , Mader Robert M. , Exner Ruth , Gnant Michael , Zielinski Christoph C. , Steger Guenther G. , Preusser Matthias , Bartsch Rupert
Published: April 2023

Supplementary table legend
Supplementary Table 1 from Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases
Authors: Bergen Elisabeth S. , Berghoff Anna S. , Medjedovic Mela , Rudas Margaretha , Fitzal Florian , Bago-Horvath Zsuzsanna , Dieckmann Karin , Mader Robert M. , Exner Ruth , Gnant Michael , Zielinski Christoph C. , Steger Guenther G. , Preusser Matthias , Bartsch Rupert
Published: April 2023

Patients characteristics of the overall population
Supplementary figures from Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15
Authors: Chen Yuhui , Sun Chuang , Landoni Elisa , Metelitsa Leonid , Dotti Gianpietro , Savoldo Barbara
Published: April 2023

Supplementary figures
Supplementary Table 4 from Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer
Authors: Rashid Naim U. , Peng Xianlu L. , Jin Chong , Moffitt Richard A. , Volmar Keith E. , Belt Brian A. , Panni Roheena Z. , Nywening Timothy M. , Herrera Silvia G. , Moore Kristin J. , Hennessey Sarah G. , Morrison Ashley B. , Kawalerski Ryan , Nayyar Apoorve , Chang Audrey E. , Schmidt Benjamin , Kim Hong Jin , Linehan David C. , Yeh Jen Jen
Published: April 2023

Table S4
Supplementary Table 2 from Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer
Authors: Rashid Naim U. , Peng Xianlu L. , Jin Chong , Moffitt Richard A. , Volmar Keith E. , Belt Brian A. , Panni Roheena Z. , Nywening Timothy M. , Herrera Silvia G. , Moore Kristin J. , Hennessey Sarah G. , Morrison Ashley B. , Kawalerski Ryan , Nayyar Apoorve , Chang Audrey E. , Schmidt Benjamin , Kim Hong Jin , Linehan David C. , Yeh Jen Jen
Published: April 2023

Table S2
Supplementary Data from The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
Authors: McCuaig Sarah , Barras David , Mann Elizabeth H. , Friedrich Matthias , Bullers Samuel J. , Janney Alina , Garner Lucy C. , Domingo Enric , Koelzer Viktor Hendrik , Delorenzi Mauro , Tejpar Sabine , Maughan Timothy S. , West Nathaniel R. , Powrie Fiona
Published: April 2023

Supplementary data to accompany manuscript
Supplementary Data from A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer
Authors: Page David B. , Pucilowska Joanna , Sanchez Katherine G. , Conrad Valerie K. , Conlin Alison K. , Acheson Anupama K. , Perlewitz Kelly S. , Imatani James H. , Aliabadi-Wahle Shaghayegh , Moxon Nicole , Mellinger Staci L. , Seino Amanda Y. , Martel Martiza , Wu Yaping , Sun Zhaoyu , Redmond William L. , Rajamanickam Venkatesh , Waddell Dottie , Laxague Deborah , Shah Monil , Chang Shu-Ching , Urba Walter J.
Published: April 2023

Supp. Figures1-8
Supplementary Data #1 from Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma
Authors: Zhu Guo Gord , Nafa Khedoudja , Agaram Narasimhan , Zehir Ahmet , Benayed Ryma , Sadowska Justyna , Borsu Laetitia , Kelly Ciara , Tap William D. , Fabbri Nicola , Athanasian Edward , Boland Patrick J. , Healey John H. , Berger Michael F. , Ladanyi Marc , Hameed Meera
Published: April 2023

IMPACT_Gene_List_4_platforms
Supplementary Data from Cancer-associated Fibroblast–promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma
Authors: Zhang Hongfang , Hua Yuhui , Jiang Zhenzhen , Yue Jing , Shi Ming , Zhen Xiaoli , Zhang Xiaoyan , Yang Ling , Zhou Rongjing , Wu Shixiu
Published: April 2023

Supplementary Figure. S1. The expression of DNM3OS in esophageal cancer cells after transfection with DNM3OS siRNA.
Supplementary Data from Cancer-associated Fibroblast–promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma
Authors: Zhang Hongfang , Hua Yuhui , Jiang Zhenzhen , Yue Jing , Shi Ming , Zhen Xiaoli , Zhang Xiaoyan , Yang Ling , Zhou Rongjing , Wu Shixiu
Published: April 2023

Supplementary Figure. S2. The expression of DNM3OS in esophageal cancer cells following irradiation.
Supplementary Data 3 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Authors: Wen Patrick Y. , Reardon David A. , Armstrong Terri S. , Phuphanich Surasak , Aiken Robert D. , Landolfi Joseph C. , Curry William T. , Zhu Jay-Jiguang , Glantz Michael , Peereboom David M. , Markert James M. , LaRocca Renato , O'Rourke Donald M. , Fink Karen , Kim Lyndon , Gruber Michael , Lesser Glenn J. , Pan Edward , Kesari Santosh , Muzikansky Alona , Pinilla Clemencia , Santos Radleigh G. , Yu John S.
Published: April 2023

Supplemental Fig 3
Supplementary tables from A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer
Authors: Singh Thoudam Debraj , Song Jaeyoung , Kim Jina , Chin Jungwook , Ji Hyun Dong , Lee Jae-Eon , Lee Sang Bong , Yoon Heeseok , Yu Ji Hoon , Kim Sang Kyoon , Yoon Ghil Suk , Hwang Hayoung , Lee Ho Won , Oh Ji Min , Lee Sang-Woo , Lee Jaetae , Choi Hueng-Sik , Na Soon-Young , Choi Won-Il , Park Young Joo , Song Young Shin , Kim Young A. , Lee In-Kyu , Cho Sung Jin , Jeon Yong Hyun
Published: April 2023

Supplementary tables
Table S5 from The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Authors: Spriano Filippo , Chung Elaine Yee Lin , Gaudio Eugenio , Tarantelli Chiara , Cascione Luciano , Napoli Sara , Jessen Katti , Carrassa Laura , Priebe Valdemar , Sartori Giulio , Graham Garrett , Selvanathan Saravana P. , Cavalli Andrea , Rinaldi Andrea , Kwee Ivo , Testoni Monica , Genini Davide , Ye B. Hilda , Zucca Emanuele , Stathis Anastasios , Lannutti Brian , Toretsky Jeffrey A. , Bertoni Francesco
Published: April 2023

Gene expression data after YK-4-279 or TK-216 treatment (18h) in U2932, TMD8, OCILY10 and SUDHL2. A) Supervised analysis of transcriptome after treatment. B) Gene-sets significantly enriched after treatment.
Table S4 from The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Authors: Spriano Filippo , Chung Elaine Yee Lin , Gaudio Eugenio , Tarantelli Chiara , Cascione Luciano , Napoli Sara , Jessen Katti , Carrassa Laura , Priebe Valdemar , Sartori Giulio , Graham Garrett , Selvanathan Saravana P. , Cavalli Andrea , Rinaldi Andrea , Kwee Ivo , Testoni Monica , Genini Davide , Ye B. Hilda , Zucca Emanuele , Stathis Anastasios , Lannutti Brian , Toretsky Jeffrey A. , Bertoni Francesco
Published: April 2023

Gene expression data after YK-4-279 treatment (4-8h) in U2932 and TMD8. A) Supervised analysis of gene expression profiling after treatment; B) Gene-sets significantly enriched after treatment; C) SPIB/IRF4/lenalidomide regulated gene-sets significantly enriched after treatment.
Table S3 from The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Authors: Spriano Filippo , Chung Elaine Yee Lin , Gaudio Eugenio , Tarantelli Chiara , Cascione Luciano , Napoli Sara , Jessen Katti , Carrassa Laura , Priebe Valdemar , Sartori Giulio , Graham Garrett , Selvanathan Saravana P. , Cavalli Andrea , Rinaldi Andrea , Kwee Ivo , Testoni Monica , Genini Davide , Ye B. Hilda , Zucca Emanuele , Stathis Anastasios , Lannutti Brian , Toretsky Jeffrey A. , Bertoni Francesco
Published: April 2023

YK-4-279 and TK-216 combinations. For each combination, the table shows the median Combination Index (CI) obtained after exposing cell lines to increasing concentration of two compounds at 8 x 8 concentrations of each compound (removing concentrations that give 10% or less of proliferation already with the single agent), as previously performed (3).
Supplementary Data from The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Authors: Spriano Filippo , Chung Elaine Yee Lin , Gaudio Eugenio , Tarantelli Chiara , Cascione Luciano , Napoli Sara , Jessen Katti , Carrassa Laura , Priebe Valdemar , Sartori Giulio , Graham Garrett , Selvanathan Saravana P. , Cavalli Andrea , Rinaldi Andrea , Kwee Ivo , Testoni Monica , Genini Davide , Ye B. Hilda , Zucca Emanuele , Stathis Anastasios , Lannutti Brian , Toretsky Jeffrey A. , Bertoni Francesco
Published: April 2023

Supplementary materials (figures and table legends)
Figure S1 from Depression-Induced Neuropeptide Y Secretion Promotes Prostate Cancer Growth by Recruiting Myeloid Cells
Authors: Cheng Yan , Tang Xin-Ying , Li Yi-Xuan , Zhao Dan-Dan , Cao Qiu-Hua , Wu Hong-Xi , Yang Hong-Bao , Hao Kun , Yang Yong
Published: April 2023

Gating strategy for tumor immune cell analysis by flow cytometry.
Table S4 from BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Authors: Walsh Louise , Haley Kathryn E. , Moran Bruce , Mooney Brian , Tarrant Finbarr , Madden Stephen F. , Di Grande Alessandra , Fan Yue , Das Sudipto , Rueda Oscar M. , Dowling Catríona M. , Varešlija Damir , Chin Suet-Feung , Linn Sabine , Young Leonie S. , Jirström Karin , Crown John P. , Bernards Rene , Caldas Carlos , Gallagher William M. , O'Connor Darran P. , Ní Chonghaile Tríona
Published: April 2023

Table S4: Multivariate analysis on RATHER RNA-seq data
Supplementary Data from An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option
Authors: Manzotti Gloria , Torricelli Federica , Benedetta Donati , Lococo Filippo , Sancisi Valentina , Rossi Giulio , Piana Simonetta , Ciarrocchi Alessia
Published: April 2023

Supplementary Figure Legends, Supplementary Tables, Supplementary Materials and Methods
Figure S6 (A-D) from Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Authors: Alvarez Secord Angeles , Bell Burdett Kirsten , Owzar Kouros , Tritchler David , Sibley Alexander B. , Liu Yingmiao , Starr Mark D. , Brady J. Chris , Lankes Heather A. , Hurwitz Herbert I. , Mannel Robert S. , Tewari Krishnansu S. , O'Malley David M. , Gray Heidi , Bakkum-Gamez Jamie N. , Fujiwara Keiichi , Boente Matthew , Deng Wei , Burger Robert A. , Birrer Michael J. , Nixon Andrew B.
Published: April 2023

3-way interaction analyses between outcome, treatment, and markers.
Table S1 from Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Authors: Weinmann Sheila , Leo Michael C. , Francisco Melanie , Jenkins Charisma L. , Barry Todd , Leesman Glen , Linke Steven P. , Whitworth Pat W. , Patel Rakesh , Pellicane James , Wärnberg Fredrik , Bremer Troy
Published: April 2023

Clinical and pathologic characteristics of evaluable KPNW study subjects compared to non-evaluable KPNW subjects among eligible study cases
Figure S1 from Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Authors: Weinmann Sheila , Leo Michael C. , Francisco Melanie , Jenkins Charisma L. , Barry Todd , Leesman Glen , Linke Steven P. , Whitworth Pat W. , Patel Rakesh , Pellicane James , Wärnberg Fredrik , Bremer Troy
Published: April 2023

Consort diagram describing eligible and evaluable patients
Supplementary methods from Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes
Authors: Shin Myeong-Kyun , Payne Susan , Bilger Andrea , Matkowskyj Kristina A. , Carchman Evie , Meyer Dominique S. , Bentires-Alj Mohamed , Deming Dustin A. , Lambert Paul F.
Published: April 2023

Supplementary methods
Table S1 from ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia
Authors: Xu Heng , Zhao Xujie , Bhojwani Deepa , E Shuyu , Goodings Charnise , Zhang Hui , Seibel Nita L. , Yang Wentao , Li Chunliang , Carroll William L. , Evans William E. , Yang Jun J.
Published: April 2023

Table S1 shows that downregulation of ARID5B led to more increases in LC50 of MTX and 6-MP than other antileukemic drugs
Figure S3 from Postablation Modulation after Single High-Dose Radiation Therapy Improves Tumor Control via Enhanced Immunomodulation
Authors: Savage Talicia , Pandey Sanjay , Guha Chandan
Published: April 2023

PET scan of 4T1 metastases.
Figure S1 from Postablation Modulation after Single High-Dose Radiation Therapy Improves Tumor Control via Enhanced Immunomodulation
Authors: Savage Talicia , Pandey Sanjay , Guha Chandan
Published: April 2023

Increased lymphocytes in secondary lymphoid organs.
Supplementary Figure S5 from Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma
Authors: Mitani Yoshitsugu , Lin Sue-Hwa , Pytynia Kristen B. , Ferrarotto Renata , El-Naggar Adel K.
Published: April 2023

No impact of Mifepristone and Enzalutamide treatments on cell colony formation in SDC-04.